RiboX therapeutics announces FDA clearance for IND application of RXRG001
October 26, 2024 | 00:24
RiboX Therapeutics Ltd, a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, announced that the US Food and Drug Administration has cleared its IND application for the Phase I/IIa Study of RXRG001 on October 25 th, 2024.
Mobile Version